IE53374B1 - Eye-lotion composition intended for the treatment of conjunctivites and keratites - Google Patents
Eye-lotion composition intended for the treatment of conjunctivites and keratitesInfo
- Publication number
- IE53374B1 IE53374B1 IE1216/82A IE121682A IE53374B1 IE 53374 B1 IE53374 B1 IE 53374B1 IE 1216/82 A IE1216/82 A IE 1216/82A IE 121682 A IE121682 A IE 121682A IE 53374 B1 IE53374 B1 IE 53374B1
- Authority
- IE
- Ireland
- Prior art keywords
- eye
- lotion
- keratites
- treatment
- conjunctivites
- Prior art date
Links
- 239000006210 lotion Substances 0.000 title claims abstract description 47
- 239000000203 mixture Substances 0.000 title claims description 14
- 229910021538 borax Inorganic materials 0.000 claims abstract description 6
- 235000010339 sodium tetraborate Nutrition 0.000 claims abstract description 6
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000007864 aqueous solution Substances 0.000 claims abstract description 4
- 239000006172 buffering agent Substances 0.000 claims abstract description 4
- 239000007951 isotonicity adjuster Substances 0.000 claims abstract description 4
- 230000003139 buffering effect Effects 0.000 claims abstract description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 5
- 239000004327 boric acid Substances 0.000 claims description 5
- 239000001294 propane Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 208000022873 Ocular disease Diseases 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 239000008213 purified water Substances 0.000 claims description 2
- ZRJOUVOXPWNFOF-UHFFFAOYSA-N 3-dodecoxypropan-1-amine Chemical compound CCCCCCCCCCCCOCCCN ZRJOUVOXPWNFOF-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- 240000001606 Adenanthera pavonina Species 0.000 description 10
- 235000011470 Adenanthera pavonina Nutrition 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 244000052616 bacterial pathogen Species 0.000 description 9
- 231100000111 LD50 Toxicity 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 230000003505 mutagenic effect Effects 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 230000002421 anti-septic effect Effects 0.000 description 5
- YPQVDFLBDPTGLB-UHFFFAOYSA-N cethexonium Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)C1CCCCC1O YPQVDFLBDPTGLB-UHFFFAOYSA-N 0.000 description 4
- 229950000924 cethexonium Drugs 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000700198 Cavia Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 230000003228 microsomal effect Effects 0.000 description 3
- 231100000219 mutagenic Toxicity 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 229930195730 Aflatoxin Natural products 0.000 description 2
- XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 206010015946 Eye irritation Diseases 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 241000295644 Staphylococcaceae Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000005409 aflatoxin Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 230000010093 eczematous lesion Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 231100000013 eye irritation Toxicity 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 150000002730 mercury Chemical class 0.000 description 2
- -1 methylene blue Chemical class 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- PPQNQXQZIWHJRB-UHFFFAOYSA-N Methylcholanthrene Chemical compound C1=CC=C2C3=CC4=CC=C(C)C(CC5)=C4C5=C3C=CC2=C1 PPQNQXQZIWHJRB-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 231100000132 chronic toxicity testing Toxicity 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000000554 iris Anatomy 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 231100000243 mutagenic effect Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 231100000458 skin sensitization testing Toxicity 0.000 description 1
- SKIVFJLNDNKQPD-UHFFFAOYSA-N sulfacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 description 1
- 229960002673 sulfacetamide Drugs 0.000 description 1
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical class NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 206010044325 trachoma Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8111035A FR2507083A1 (fr) | 1981-06-04 | 1981-06-04 | Composition pour collyre a base d'amino-1 dodecycloxy-3 propane, destine au traitement des conjonctivites et keratites |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE821216L IE821216L (en) | 1982-12-04 |
| IE53374B1 true IE53374B1 (en) | 1988-10-26 |
Family
ID=9259171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE1216/82A IE53374B1 (en) | 1981-06-04 | 1982-05-20 | Eye-lotion composition intended for the treatment of conjunctivites and keratites |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0067084B1 (enrdf_load_stackoverflow) |
| AT (1) | ATE9136T1 (enrdf_load_stackoverflow) |
| DE (1) | DE3260622D1 (enrdf_load_stackoverflow) |
| ES (1) | ES8506999A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2507083A1 (enrdf_load_stackoverflow) |
| GR (1) | GR75441B (enrdf_load_stackoverflow) |
| IE (1) | IE53374B1 (enrdf_load_stackoverflow) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3291683A (en) * | 1965-05-24 | 1966-12-13 | American Cyanamid Co | Controlling fungi and bacteria with alkoxy or alkylthio alkylamine ethers |
| GB1369250A (en) * | 1970-08-07 | 1974-10-02 | Pfizer | Amines the preparation thereof and their use in pharmacejtical compositions |
| DE2252487C3 (de) * | 1972-10-26 | 1979-07-19 | Th. Goldschmidt Ag, 4300 Essen | Propanolamin-Derivate und deren Verwendung als Mikrobicide |
-
1981
- 1981-06-04 FR FR8111035A patent/FR2507083A1/fr active Granted
-
1982
- 1982-05-07 EP EP82400843A patent/EP0067084B1/fr not_active Expired
- 1982-05-07 GR GR68095A patent/GR75441B/el unknown
- 1982-05-07 AT AT82400843T patent/ATE9136T1/de not_active IP Right Cessation
- 1982-05-07 DE DE8282400843T patent/DE3260622D1/de not_active Expired
- 1982-05-20 IE IE1216/82A patent/IE53374B1/en unknown
- 1982-06-01 ES ES512751A patent/ES8506999A1/es not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| DE3260622D1 (en) | 1984-10-04 |
| EP0067084A1 (fr) | 1982-12-15 |
| EP0067084B1 (fr) | 1984-08-29 |
| ES512751A0 (es) | 1985-09-16 |
| ES8506999A1 (es) | 1985-09-16 |
| GR75441B (enrdf_load_stackoverflow) | 1984-07-17 |
| FR2507083A1 (fr) | 1982-12-10 |
| IE821216L (en) | 1982-12-04 |
| FR2507083B1 (enrdf_load_stackoverflow) | 1983-12-30 |
| ATE9136T1 (de) | 1984-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6479532B1 (en) | Antifungal compositions | |
| KR920001461B1 (ko) | 안과 액제의 제조방법 | |
| Houang et al. | Absence of bacterial resistance to povidone iodine. | |
| Jawetz | Infections with Pseudomonas aeruginosa treated with polymyxin B | |
| US6348190B1 (en) | Pharmaceutical compositions with antimicrobial activity | |
| KLEINFELD et al. | Effects of topical anesthetics on growth of microorganisms | |
| WO1997000076A1 (en) | Compositions containing poly(hexamethylene biguanide) salts and uses thereof | |
| Quesnel et al. | Synergism between chlorhexidine and sulphadiazine | |
| US5762940A (en) | Methods and compositions for inhibiting or destroying viruses or retroviruses | |
| EP1128809A1 (en) | Aqueous ophthalmic formulations comprising chitosan | |
| IE53374B1 (en) | Eye-lotion composition intended for the treatment of conjunctivites and keratites | |
| RU2161961C1 (ru) | Лекарственный препарат | |
| US3985873A (en) | Solution containing trimethoprim, sulfacetamide and polymyxin | |
| Schuhman et al. | Clinical experience with povidone-iodine eye drops in patients with conjunctivitis and keratoconjunctivitis | |
| SERY et al. | Novobiocin, a new antibiotic: ocular penetration and tolerance | |
| EP1171107A1 (de) | Pharmazeutische zusammensetzung wirksam gegen durch bakterien, viren, pilze, hefen und protozoen verursachte krankheitszustände | |
| IE54426B1 (en) | Therapeutic composition based inosine monophosphate for the treatment of eye accommodation disorders | |
| US4190673A (en) | Colchicine ophthalmic composition and method of use | |
| KR20010022033A (ko) | 가축의 유선염 치료방법 | |
| US4288609A (en) | Quaternary ammonium derivatives of adamantane with antimicrobic activity | |
| EP0556051B1 (en) | Use of bilobalide and derivatives thereof for treating an infection in an individual and pharmaceutical compositions adapted for such use | |
| US4897404A (en) | Anti-infective methods and compositions | |
| EP0076430B1 (en) | Compositions having antimicrobial activity | |
| US11351192B2 (en) | De-colonization drug, preparation method therefor, and application thereof | |
| Macdonald | Ps. pyocyaneus eye infection |